1 Similarly, the active ingredient tirzepatide is marketed by Eli Lilly as two separate drugs under the brand names Mounjaro (injection for diabetes, approved in 2022) and Zepbound (injection for weight loss, approved in 2023)
No submission has been publicly announced as of this writing
Back Lau, J, Bloch, K, Schffer, L, et al (24 Sept 2015) 'Discovery of the once-weekly glucagon-like peptide-1 (glp-1) analogue Semaglutide', Journal Medicinal Chemistry , 58/18
Optimizing when and how you take BPC-157 can influence its effectiveness
Packaging Package content: 150 capsules
This probably reflects an effort by insurers to deter off-label use of GLP-1s for weight loss